Levodopa is the mainstay of treatment for Parkinson’s disease, but it is unable to halt the progression of the disease, and it is also associated with undesirable side effects, including motor fluctuations and dyskinesia. This Review highlights new therapeutic strategies in Parkinson's disease, including neuroprotective therapies and non-dopaminergic drugs, as well as improvements to the existing dopaminergic drugs.
- Carlo Colosimo
- Giovanni Fabbrini
- Alfredo Berardelli